Life-threatening bullous skin eruptions during interleukin-2 therapy.
Staunton
M R
MR
Department of Medicine, University of California, San Francisco 94143-0128.
Scully
M C
MC
Le Boit
P E
PE
Aronson
F R
FR
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D007376:Interleukin-2